Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.03 +6.1%	$2.69	$1.89 ▼ $4.11	$1.13B	0.62	3.44 million shs	7.34 million shs
CMPS COMPASS Pathways	$3.31 +1.5%	$3.98	$2.25 ▼ $8.54	$305.01M	2.12	1.23 million shs	1.95 million shs
CVAC CureVac	$5.41 -0.7%	$4.49	$2.37 ▼ $5.72	$1.22B	2.53	783,645 shs	883,637 shs
PAHC Phibro Animal Health	$29.90 +6.8%	$23.60	$16.16 ▼ $30.74	$1.13B	0.75	215,504 shs	557,250 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+5.40%	+55.94%	+85.61%	+41.45%
CMPS COMPASS Pathways	0.00%	+17.65%	-32.10%	+20.70%	-47.44%
CVAC CureVac	0.00%	+0.28%	+22.34%	+103.58%	+63.98%
PAHC Phibro Animal Health	0.00%	+9.08%	+16.24%	+50.00%	+66.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.4235 of 5 stars	3.4	1.0	0.0	0.0	3.1	3.3	0.0
CMPS COMPASS Pathways	1.9583 of 5 stars	3.4	2.0	0.0	0.0	1.8	0.8	0.6
CVAC CureVac	4.4942 of 5 stars	4.1	5.0	0.0	4.9	0.0	0.0	1.3
PAHC Phibro Animal Health	3.6637 of 5 stars	0.9	2.0	2.5	1.1	3.0	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.80	Moderate Buy	$7.50	86.10% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	413.60% Upside
CVAC CureVac	2.20	Hold	$6.83	26.31% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-18.39% Downside

Current Analyst Ratings Breakdown

Latest CMPS, CVAC, PAHC, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	41.71	N/A	N/A	$3.58 per share	1.13
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
CVAC CureVac	$579.18M	2.10	$0.87 per share	6.24	$3.36 per share	1.61
PAHC Phibro Animal Health	$1.02B	1.19	$2.26 per share	13.25	$6.34 per share	4.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/5/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
CVAC CureVac	$175.50M	$0.92	5.88	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	38.33	14.24	0.47	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest CMPS, CVAC, PAHC, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
4/10/2025	Q4 2024	CVAC CureVac	-$0.14	-$0.15	-$0.01	-$0.15	$6.40 million	$15.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.61%	N/A	61.54%	N/A

Latest CMPS, CVAC, PAHC, and ABCL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
CMPS COMPASS Pathways	0.11	10.18	10.18
CVAC CureVac	0.05	7.65	7.64
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CMPS COMPASS Pathways	46.19%
CVAC CureVac	17.26%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
CMPS COMPASS Pathways	3.93%
CVAC CureVac	N/A
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
CVAC CureVac	880	224.34 million	N/A	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

CMPS, CVAC, PAHC, and ABCL Headlines

Recent News About These Companies

Overlooked Stock: PAHC Taps 4-Year High

5 hours ago | youtube.comY

Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

July 7 at 2:30 PM | benzinga.com

Phibro Animal Health stock surges after JPMorgan upgrade to Overweight

July 7 at 12:17 PM | in.investing.com

Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up - Still a Buy?

July 7 at 10:39 AM | marketbeat.com

Phibro Animal Health (NASDAQ:PAHC) Upgraded to Overweight at JPMorgan Chase & Co.

July 7 at 8:33 AM | marketbeat.com

Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue? - Nasdaq

July 3, 2025 | nasdaq.com

Phibro Animal Health Corporation (PAHC) - Investing.com

July 3, 2025 | investing.com

Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise? - Nasdaq

July 3, 2025 | nasdaq.com

Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue?

July 2, 2025 | zacks.com

Phibro Animal Health (NASDAQ:PAHC) Hits New 1-Year High - Here's What Happened

July 2, 2025 | marketbeat.com

Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise?

July 1, 2025 | zacks.com

Phibro Animal Health (NASDAQ:PAHC) versus Metastat (OTCMKTS:MTST) Critical Comparison

July 1, 2025 | americanbankingnews.com

PAHC vs. BSX: Which Stock Is the Better Value Option?

June 30, 2025 | zacks.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

June 30, 2025 | zacks.com

Phibro Animal Health (NASDAQ:PAHC) PT Set at $26.00 by Morgan Stanley

June 27, 2025 | americanbankingnews.com

Morgan Stanley Raises Phibro Animal Health (NASDAQ:PAHC) Price Target to $26.00

June 25, 2025 | marketbeat.com

Investors in Phibro Animal Health (NASDAQ:PAHC) have seen decent returns of 45% over the past year

June 25, 2025 | finance.yahoo.com

Best Growth Stocks to Buy for June 25th

June 25, 2025 | zacks.com

Phibro Animal Health Corporation (PAHC) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Is Phibro (PAHC) a Solid Growth Stock? 3 Reasons to Think "Yes"

June 23, 2025 | zacks.com

Zacks Research Issues Optimistic Forecast for PAHC Earnings

June 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, CVAC, PAHC, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.03 +0.23 (+6.05%)

Closing price 04:00 PM Eastern

Extended Trading

$4.03 0.00 (-0.12%)

As of 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

COMPASS Pathways NASDAQ:CMPS

$3.31 +0.05 (+1.53%)

Closing price 04:00 PM Eastern

Extended Trading

$3.32 +0.00 (+0.15%)

As of 07:59 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CureVac NASDAQ:CVAC

$5.41 -0.04 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$5.38 -0.03 (-0.55%)

As of 07:52 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Phibro Animal Health NASDAQ:PAHC

$29.90 +1.90 (+6.79%)

Closing price 04:00 PM Eastern

Extended Trading

$29.68 -0.22 (-0.74%)

As of 07:35 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time